Fueling the revolution: RIBOTACs manipulating RNA decay

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Existing RNA-targeting therapeutics face limitations.
• Certain disease-causing transcripts are considered 'undruggable'.
• RNase L is an endogenous enzyme with potent RNA degradation capabilities.

Purpose of the Study:

• To introduce and describe Ribonuclease-targeting chimeras (RIBOTACs) as a novel therapeutic modality.
• To highlight the mechanism of action of RIBOTACs in targeting specific RNA transcripts.
• To explore the potential of RIBOTACs in oncology applications.

Main Methods:

• Design of RIBOTACs by conjugating small-molecule RNA binders with RNase L-recruiting moieties.
• Utilizing the endogenous RNase L pathway for catalytic RNA degradation.
• Investigating the efficacy of RIBOTACs against previously 'undruggable' RNA targets.

Main Results:

• RIBOTACs demonstrate catalytic degradation of targeted RNA transcripts.
• The mechanism circumvents limitations associated with conventional RNA-targeted therapies.
• Potential for broad application in oncology by targeting key oncogenic transcripts.

Conclusions:

• RIBOTACs represent an innovative class of RNA-targeting molecules.
• Their unique mechanism offers a promising therapeutic strategy for oncology.
• RIBOTACs expand the druggable RNA target space for cancer treatment.